Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: DMB who wrote (1522)	4/2/1998 2:25:00 AM
From: Maurice Winn	Read Replies (2) \| Respond to of 1762

Well, statistics with a sample of one beats a sample of none! If there are dozens of people per practice with one needing Rituxan in 3 months, then with 100,000 low grade CD20 cases extant, there would be 1:30 needing treatment = 3,000 in the USA treated over the past 4 months. Give or take a few. Have oncologists found anything different from the Phase III trials? Excessive intractable tuberculosis in people without AIDS? Now my linear regression analysis on that one person says that there should be some fairly solid evidence of the effects on 1,000 of those people since they must have been treated at least 2 months ago. I suppose IDEC will be gathering all the statistics they can as quickly as they can in the hope of showing great efficacy for Rituxan. When do you think results will be reported on large numbers of people? Thanks DMB for kindly offering your experience so far. I can see that somebody who has been given CHOP and 40 Grays would be looking very keenly for something else - especially if the first treatment failed to stop the lymphoma. I realize the low grades don't fully respond to chemotherapy. And that my numbers are very approximate - maybe there are twice that number of people with low grade. Regards, Maurice PS: Meanwhile, Tarken has finished his 40 Grays of cervical upper thorax radiation and as far as we can tell, that is the end of it all. Fingers crossed of course. Maybe it was just a wart in his neck - for all we know, given the total absence of any other sypmptom, it might as well have been. Nevertheless, I retain a close interest in things cancer in general and lymphoma in particular.